Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma

NCT04323956 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04323956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04323956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 15, 2020
Completion date
May 16, 2028
Enrollment
50 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage ii diffuse large b-cell lymphoma, ann arbor stage ii follicular lymphoma, ann arbor stage ii marginal zone lymphoma, ann arbor stage iii diffuse large b-cell lymphoma, ann arbor stage iii follicular lymphoma, ann arbor stage iii marginal zone lymphoma, ann arbor stage iv diffuse large b-cell lymphoma, ann arbor stage iv follicular lymphoma, ann arbor stage iv marginal zone lymphoma, diffuse large b-cell lymphoma, high grade b-cell lymphoma with myc and bcl2 and/or bcl6 rearrangements, high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, indolent non-hodgkin lymphoma